Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sankar D Navaneethan

Showing results (21-30 of 281) with videos related to

Pageof 29
Sort By:
Journal of the American Society of Nephrology : JASN|November 28, 2023
Does Serum Creatinine Reflect Muscle Mass in Patients with Kidney Failure?Sankar D Navaneethan, William E Mitch
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 20, 2022
Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?L Parker Gregg, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|August 16, 2015
BP Targets in Older Adults with CKD: Additional Evidence, but Uncertainty ContinuesSankar D Navaneethan, Adam Whaley-Connell
Journal of the American Heart Association|July 16, 2017
Omega-3 Fatty Acids (Fish Oil) Supplementation and Albuminuria: Not a Slam DunkSankar D Navaneethan, Salim S Virani
The American Journal of Medicine|May 27, 2008
Lack of permanent access in late referrals and its implications: not to be forgottenSankar D Navaneethan, Sagar U Nigwekar
Clinical Journal of the American Society of Nephrology : CJASN|July 27, 2019
Bariatric Surgery for ESKD Patients: Why, When, and How?Kevin F Erickson, Sankar D Navaneethan
Kidney International|February 27, 2021
Early eGFR decline after SGLT2i initiation: knowns and unknownsL Parker Gregg, Sankar D Navaneethan
The Journal of Clinical Endocrinology and Metabolism|September 25, 2025
Impact of SGLT2 inhibitors on glomerular filtration in type 1 diabetesMichael W Holliday, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|April 10, 2026
Expanding Evidence for Glucagon-Like Peptide-1 Receptor Agonists in Those with Diabetes and Kidney DiseaseMichael W Holliday, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|August 10, 2013
Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?Sankar D Navaneethan, Emmanuel L Bravo
Pageof 29

Showing results (21-30 of 281) with videos related to

Sort By:
Pageof 29
Journal of the American Society of Nephrology : JASN|November 28, 2023
Does Serum Creatinine Reflect Muscle Mass in Patients with Kidney Failure?Sankar D Navaneethan, William E Mitch
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 20, 2022
Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?L Parker Gregg, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|August 16, 2015
BP Targets in Older Adults with CKD: Additional Evidence, but Uncertainty ContinuesSankar D Navaneethan, Adam Whaley-Connell
Journal of the American Heart Association|July 16, 2017
Omega-3 Fatty Acids (Fish Oil) Supplementation and Albuminuria: Not a Slam DunkSankar D Navaneethan, Salim S Virani
The American Journal of Medicine|May 27, 2008
Lack of permanent access in late referrals and its implications: not to be forgottenSankar D Navaneethan, Sagar U Nigwekar
Clinical Journal of the American Society of Nephrology : CJASN|July 27, 2019
Bariatric Surgery for ESKD Patients: Why, When, and How?Kevin F Erickson, Sankar D Navaneethan
Kidney International|February 27, 2021
Early eGFR decline after SGLT2i initiation: knowns and unknownsL Parker Gregg, Sankar D Navaneethan
The Journal of Clinical Endocrinology and Metabolism|September 25, 2025
Impact of SGLT2 inhibitors on glomerular filtration in type 1 diabetesMichael W Holliday, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|April 10, 2026
Expanding Evidence for Glucagon-Like Peptide-1 Receptor Agonists in Those with Diabetes and Kidney DiseaseMichael W Holliday, Sankar D Navaneethan
Clinical Journal of the American Society of Nephrology : CJASN|August 10, 2013
Aldosterone breakthrough during angiotensin receptor blocker use: more questions than answers?Sankar D Navaneethan, Emmanuel L Bravo
Pageof 29